NCT04684602 Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions
| NCT ID | NCT04684602 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Thomas Advanced Medical LLC |
| Condition | Autoimmune Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2020-07-09 |
| Primary Completion | 2030-07-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 5,000 participants in total. It began in 2020-07-09 with a primary completion date of 2030-07-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This multi-arm, multi-site study investigates the safety, tolerability, and efficacy of stem cell therapy for the treatment of various acute and chronic conditions. Clinically observed initial findings and an extensive body of research indicate regenerative treatments are both safe and effective for the treatment of multiple conditions.
Eligibility Criteria
Inclusion Criteria: * Age 18 and older * Ability to provide informed consent * Availability for follow up visits Exclusion Criteria: * Active or recent malignancy (within last 2 years) * Pregnancy or breast-feeding * Inability to provide informed consent
Contact & Investigator
Ernst R Von Schwarz, MD, PhD
PRINCIPAL INVESTIGATOR
HeartStem Institute, Southern California Hospital at Culver City
Frequently Asked Questions
Who can join the NCT04684602 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Autoimmune Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT04684602 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT04684602 currently recruiting?
Yes, NCT04684602 is actively recruiting participants. Contact the research team at paul@thomasadvancedmedical.com for enrollment information.
Where is the NCT04684602 trial being conducted?
This trial is being conducted at Culver City, United States.
Who is sponsoring the NCT04684602 clinical trial?
NCT04684602 is sponsored by Thomas Advanced Medical LLC. The principal investigator is Ernst R Von Schwarz, MD, PhD at HeartStem Institute, Southern California Hospital at Culver City. The trial plans to enroll 5,000 participants.